Early outcomes of implanting larger‐sized grafts in deceased donor liver transplantation

Background The outcomes of large‐sized graft mismatch in deceased donor liver transplantation (LT) have been rarely studied. The aim of this study was to determine whether a large‐sized graft for recipient influenced the post‐transplant outcomes. Methods A total of 273 patients undergoing LT were enrolled and divided into a large and a normal‐sized graft group by graft weight to recipient weight (GWRW) >2.5% (n = 76) or GWRW ≤2.5% (n = 197). Post‐operative complications and outcomes were retrospectively analysed. Results The two groups were comparable in demographic characteristics. The rate of complications was significantly higher in the large‐sized graft group including early allograft dysfunction (36.8% versus 17.8%, P = 0.001), hepatic necrosis (26.3% versus 13.7%, P = 0.01) and massive hydrothorax (25% versus 14.7%, P = 0.04). The large‐sized graft group suffered higher early mortality compared with the normal‐sized graft group (30 days: 14.5% versus 5.6%, P = 0.02, 90 days: 21.1% versus 9.6%, P = 0.01). The primary causes of early death were multiple organ failure (10.5% versus 2%, P = 0.002) and sepsis (2.6% versus 1.5%, P = 0.54). Four parameters including donor alanine transaminase, GWRW, estimated blood loss and model for end‐stage liver disease score were significant on multivariate analysis, and indicated significant risk factors for the early mortality of recipients. Conclusion In deceased donor LT, GWRW >2.5% is associated with increased liver injury, risk of early mortality and other adverse outcomes. Thus, donor livers should be allocated to recipients with GWRW ≤2.5%. The outcomes of implanting a large‐sized donor liver in deceased transplantation remain unclear. In this study, we confirmed graft weight to recipient weight (GWRW) threshold of 2.5% and found that the GWRW ratio >2.5% is associated with increased risk of early mortality and other adverse outcomes. It should be prudent to transplant a GWRW >2.5% donor liver to the recipient with high model for end‐stage liver disease score and donor alanine transaminase for clinicians. This finding may confirm the classic hypotheses for the threshold of GWRW and may also have an impact on the future clinical decision‐making and the current distribution strategies of graft.